Bio-Rad Laboratories Inc. | Mid-cap | Healthcare
231,70 US$
2,11 %
| Bio-Rad Laboratories Stock Comparison:
Bio-Rad Laboratories vs Abbott LaboratoriesBio-Rad Laboratories vs Boston ScientificBio-Rad Laboratories vs MasimoBio-Rad Laboratories vs Globus MedicalBio-Rad Laboratories vs Bio-RadBio-Rad Laboratories vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2,6B
Gross Profit 1,4B 53,73 %
Operating Income 269,0M 10,48 %
Net Income -1,8B -71,86 %
EPS (Diluted) -65,36 US$

Balance Sheet Metrics

Total Assets 9,4B
Total Liabilities 2,8B
Shareholders Equity 6,6B
Debt to Equity 0,43

Cash Flow Metrics

Operating Cash Flow -2,2B
Free Cash Flow 266,2M

Revenue & Profitability Trend

Income Statement

Metric 2024 2023 2022 2021 2020
Revenue 2,6B 2,7B 2,8B 2,9B 2,5B
Cost of Goods Sold 1,2B 1,2B 1,2B 1,3B 1,1B
Gross Profit 1,4B 1,4B 1,6B 1,6B 1,4B
Operating Expenses 1,1B 1,1B 1,1B 1,1B 1,0B
Operating Income 269,0M 337,8M 475,1M 500,3M 421,3M
Pre-tax Income -2,3B -850,1M -4,7B 5,4B 4,9B
Income Tax -498,3M -212,8M -1,1B 1,2B 1,1B
Net Income -1,8B -637,3M -3,6B 4,3B 3,8B
EPS (Diluted) -65,36 US$ -21,82 US$ -121,79 US$ 140,56 US$ 126,20 US$

Income Statement Trend

Balance Sheet

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 3,0B 3,0B 3,2B 2,0B 2,1B
Non-Current Assets 6,3B 9,3B 10,3B 15,8B 10,8B
Total Assets 9,4B 12,3B 13,5B 17,8B 13,0B
Liabilities
Current Liabilities 467,8M 522,8M 568,7M 680,9M 631,5M
Non-Current Liabilities 2,3B 3,0B 3,3B 3,4B 2,5B
Total Liabilities 2,8B 3,6B 3,9B 4,1B 3,1B
Equity
Total Shareholders Equity 6,6B 8,7B 9,6B 13,7B 9,9B

Balance Sheet Composition

Cash Flow Statement

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -1,8B -637,3M -3,6B 4,3B 3,8B
Operating Cash Flow -2,2B -853,6M -5,0B 5,6B 5,0B
Investing Activities
Capital Expenditures -165,5M -156,5M -112,6M -133,7M -108,5M
Investing Cash Flow -136,8M 20,2M -1,2B -797,4M -73,3M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -238,0M -444,1M 956,0M -76,1M -543,2M
Free Cash Flow 266,2M 218,3M 80,3M 535,7M 476,4M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3,51
Forward P/E 19,84
Price to Book 0,96
Price to Sales 2,49
PEG Ratio 19,84

Profitability Ratios

Profit Margin -85,16 %
Operating Margin 9,72 %
Return on Equity -27,52 %
Return on Assets 1,55 %

Financial Health

Current Ratio 5,99
Debt to Equity 20,50
Beta 0,94

Per Share Data

EPS (TTM) -76,54 US$
Book Value per Share 241,72 US$
Revenue per Share 90,53 US$

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
bio 6,3B -3,51 0,96 -27,52 % -85,16 % 20,50
Abbott Laboratories 232,9B 17,38 4,77 30,65 % 31,89 % 27,09
Boston Scientific 147,6B 72,80 6,64 9,50 % 11,58 % 52,16
Masimo 8,7B 129,16 9,24 -25,07 % -23,25 % 72,01
Globus Medical 8,0B 43,96 1,95 4,63 % 7,39 % 2,27
Bio-Rad 6,6B -3,83 1,03 -27,52 % -85,16 % 20,50

Financial data is updated regularly. All figures are in the company's reporting currency.